Viking Therapeutics Advances Weight-Loss Pipeline with Phase 1 Trial of Novel DACRA VK3019 — Viking Therapeutics, Inc.

Event summary

Viking Therapeutics initiated a Phase 1 single ascending dose trial for VK3019, a dual amylin and calcitonin receptor agonist (DACRA), targeting weight loss.
The randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, and pharmacokinetics in healthy adults with BMI ≥30.
VK3019 follows preclinical data showing up to 8% body weight reduction in animal models within 72 hours of a single dose.
Viking is also advancing Phase 3 trials for VK2735, a dual GLP-1/GIP agonist, and plans to initiate a Phase 3 trial for oral VK2735 later this year.

The big picture

Viking Therapeutics is broadening its portfolio in the competitive weight-loss and metabolic disorder space with the initiation of a Phase 1 trial for VK3019. The move comes as the company advances its lead candidate, VK2735, through late-stage trials, aiming to differentiate itself with both oral and injectable formulations. The strategic focus on dual amylin/calcitonin receptor agonists (DACRAs) and GLP-1/GIP agonists reflects the industry’s push toward combination therapies for obesity management.

What we're watching

Pipeline Expansion: Whether VK3019 can complement or compete with Viking’s existing GLP-1/GIP agonist pipeline, particularly in the weight-loss market.
Clinical Success: The pace at which Phase 1 data for VK3019 will validate preclinical results and support further development.
Market Differentiation: How Viking’s dual-formulation strategy (oral and injectable) for VK2735 will position it against established competitors like Semaglutide and Tirzepatide.